The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?

Background & aims There has been remarkable progress in the management of hepatocellular carcinoma (HCC) during the last several decades, but its effect on the prognosis of HCC patient needs clarification. We analysed the changes that affected prognosis of HCC patients diagnosed over two differe...

Full description

Saved in:
Bibliographic Details
Published inLiver international Vol. 36; no. 3; pp. 445 - 453
Main Authors Yim, Sun Young, Seo, Yeon Seok, Jung, Chang Ho, Kim, Tae Hyung, Lee, Jae Min, Kim, Eun Sun, Keum, Bora, Jong, Young Kul, An, Hyunggin, Kim, Ji Hoon, Yim, Hyung Joon, Kim, Dong Sik, Jeen, Yoon Tae, Yeon, Jong Eun, Lee, Hong Sik, Chun, Hoon Jai, Byun, Kwan Soo, Um, Soon Ho, Kim, Chang Duck, Ryu, Ho Sang
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.03.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background & aims There has been remarkable progress in the management of hepatocellular carcinoma (HCC) during the last several decades, but its effect on the prognosis of HCC patient needs clarification. We analysed the changes that affected prognosis of HCC patients diagnosed over two different eras. Methods A retrospective study of 1318 patients diagnosed with HCC from 1986 to 2012 was conducted. Analysis was done according to two cohorts, cohort 1 (patients diagnosed with HCC from 1986 to 1992) and cohort 2 (patients diagnosed from 2006 to 2012). Results Hepatitis B virus was the most common cause of liver disease for both cohorts (66.2% and 66.0%). The proportion of patients with Barcelona Clinic Liver Cancer stage 0/A was significantly lower in cohort 1 than in cohort 2 (14.4% vs. 39.5%, P < 0.001). The proportions of patients diagnosed during surveillance and general health check‐up were significantly higher in cohort 2 than in cohort 1 (28.6% vs. 10.6% and 26.3% vs. 7.9%, respectively) while those diagnosed during symptomatic evaluation was significantly higher in cohort 1 than in cohort 2 (45.1 vs. 81.4%, P < 0.001). Surgical resection rate was similar between the two cohorts (26.1% vs 26%) while the transcatheter arterial chemoembolization rate which was the highest in cohort 1 (40.6%) was overtaken by radiofrequency ablation in cohort 2 (55%) at BCLC stage 0/A. Median survival duration in cohort 2 was significantly longer than cohort 1 (65.0 vs. 7.9 months, P < 0.001). Conclusions Implementation of national cancer surveillance and the advancement of treatment modalities have likely led to early detection of HCC and improvements in prognosis over the last 20 years.
Bibliography:ark:/67375/WNG-RW86PTWP-7
istex:B6BC0CA1A525BC06DA46C5D8E76E4A42ABF99A71
Ministry of Health and Welfare - No. HI10C2020
Korea Healthcare Technology R&D Project
ArticleID:LIV12960
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.12960